SCHEMBL23660970

SCHEMBL23660970

FC(F)(F)C(=C(C(F)(F)F)C(F)(F)F)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA9 Q16790 3/20 0.41
CA2 P00918 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
FAAH O00519 1/20 0.39
PHGDH O43175 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ALDH2 P05091 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
MGLL Q99685 1/20 0.39
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 1/20 0.38
MLYCD O95822 2/20 0.38
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP8 P22894 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23661363 0.87 MLYCD (0.36) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL17453095 0.86 CA12 (0.38) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL23660963 0.76 MLYCD (0.38) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL23660967 0.74 ALDH1A1 (0.38) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL1119466 0.73 SMN1; SMN2 (0.48) CA12CA1CA9SMN1; SMN2MEN1
SCHEMBL18288344 0.73 MEN1 (0.41) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL20319495 0.71 CA12 (0.38) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL19920498 0.71 CA12 (0.38) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL19114901 0.71 CA12 (0.38) CA12CA1CA9CA2SMN1; SMN2
SCHEMBL17453112 0.71 CA12 (0.38) CA12CA1CA9CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221776-A1 PERFLUOROAMINOOLEFINS AND METHODS OF MAKING AND USING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2021-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221776-A1 PERFLUOROAMINOOLEFINS AND METHODS OF MAKING AND USING THE SAME FGB, RFTN1, AFF1 CA12 2968/4885CA1 2040/4885CA9 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.